Literature DB >> 22228970

Outcome after gastrectomy in gastric cancer patients with type 2 diabetes.

Jong Won Kim1, Jae-Ho Cheong, Woo Jin Hyung, Seung-Ho Choi, Sung Hoon Noh.   

Abstract

AIM: To evaluate the prognosis of type II diabetes mellitus (T2DM) after gastrectomy and related factors in gastric cancer patients.
METHODS: 403 gastric cancer patients with T2DM were studied, who underwent gastrectomy between May 2003 and September 2009. A review of medical records and telephone interviews was performed in this cross-sectional study. The factors included in the statistical analysis were as follows: gender, age, type of surgery, preoperative body mass index (BMI), current BMI, BMI reduction ratio, preoperative insulin or oral diabetic medicine requirement, follow-up duration, and current state of diabetes. Assessment of diabetes status after surgery was classified into four categories according to the change in hypoglycemic agents after surgery and present status of T2DM: resolution, improvement, same, and worse.
RESULTS: The mean follow-up duration was 33.7 mo (± 20.6 mo), preoperative BMI was 24.7 kg/m(2) (± 3.0 kg/m(2)), and BMI reduction ratio was 9.8% (± 8.6%). After surgery, T2DM was cured in 58 patients (15.1%) and was improved in 117 patients (30.4%). According to the type of surgery, the BMI reduction ratio was significantly higher in the total gastrectomy and Roux-en-Y reconstruction group [14.2% ± 9.2% vs 9.2% ± 7.7% (Billroth II group), P < 0.001] and significantly lower in the subtotal gastrectomy and Billroth I reconstruction group [7.6% ± 8.0%, 9.2% ± 7.7% (Billroth II group), P < 0.001]. The BMI reduction ratio, follow-up duration after surgery, type of surgery, extent of gastrectomy, and performance of duodenal bypass were significantly correlated to the course of T2DM (P < 0.05). The BMI reduction ratio was the most influential factor on T2DM status. In a subgroup analysis of patients with a BMI reduction ratio of 10% or less (n = 206), T2DM was cured in 15 (7.6%) patients and was improved in 57 (28.8%) patients after surgery, and only the duration of surgery was significantly correlated to T2DM status (P = 0.022).
CONCLUSION: The course of T2DM was significantly correlated to the BMI reduction ratio but not to the type of surgery without a significant change in BMI.

Entities:  

Keywords:  Bariatric surgery; Diabetes mellitus; Gastric cancer; Metabolic surgery

Mesh:

Year:  2012        PMID: 22228970      PMCID: PMC3251805          DOI: 10.3748/wjg.v18.i1.49

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  The amelioration of diabetes mellitus following subtotal gastrectomy.

Authors:  M N FRIEDMAN; A J SANCETTA; G J MAGOVERN
Journal:  Surg Gynecol Obstet       Date:  1955-02

2.  Effects of subtotal gastrectomy and Roux-en-Y gastrojejunostomy on the clinical outcome of type 2 diabetes mellitus.

Authors:  Juntao Yang; Chunxue Li; Hongming Liu; Hongguang Gu; Ping Chen; Baohua Liu
Journal:  J Surg Res       Date:  2010-07-30       Impact factor: 2.192

3.  Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.

Authors:  Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Journal:  N Engl J Med       Date:  2004-12-23       Impact factor: 91.245

Review 4.  The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus.

Authors:  Francesco Rubino; Lee M Kaplan; Philip R Schauer; David E Cummings
Journal:  Ann Surg       Date:  2010-03       Impact factor: 12.969

Review 5.  Potential of surgery for curing type 2 diabetes mellitus.

Authors:  Francesco Rubino; Michel Gagner
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

6.  A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut?

Authors:  M S Hickey; W J Pories; K G MacDonald; K A Cory; G L Dohm; M S Swanson; R G Israel; H A Barakat; R V Considine; J F Caro; J A Houmard
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

Review 7.  Neuro-modulation and bariatric surgery for type 2 diabetes mellitus.

Authors:  D Spector; S Shikora
Journal:  Int J Clin Pract Suppl       Date:  2010-02

Review 8.  Why is type 1 diabetes uncommon in Asia?

Authors:  Yongsoo Park
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

9.  Safety, effectiveness, and cost effectiveness of metabolic surgery in the treatment of type 2 diabetes mellitus.

Authors:  Nestor Villamizar; Aurora D Pryor
Journal:  J Obes       Date:  2010-11-14

10.  Role of the incretin system in the remission of type 2 diabetes following bariatric surgery.

Authors:  G Mingrone
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-10       Impact factor: 4.222

View more
  36 in total

1.  Improvement of type 2 diabetes mellitus after gastric cancer surgery: short-term outcome analysis after gastrectomy.

Authors:  Ji Yeong An; Yoo Min Kim; Min Ah Yun; Byeong Hee Jeon; Sung Hoon Noh
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Predictors of long-term diabetes remission after metabolic surgery.

Authors:  Ming Hsien Lee; Wei-Jei Lee; Keong Chong; Jung-Chien Chen; Kong-Han Ser; Yi-Chih Lee; Shu-Chun Chen
Journal:  J Gastrointest Surg       Date:  2015-04-04       Impact factor: 3.452

3.  Does Roux-en-Y gastrectomy for gastric cancer influence glucose homeostasis in lean patients?

Authors:  Silvia Y Hayashi; Joel Faintuch; Osmar K Yagi; Camila M Yamaguchi; Jacob J Faintuch; Ivan Cecconello
Journal:  Surg Endosc       Date:  2013-02-23       Impact factor: 4.584

4.  Nutritional safety of oncometabolic surgery for early gastric cancer patients: a prospective single-arm pilot study using a historical control group for comparison.

Authors:  Young Suk Park; Do Joong Park; Ki Hyun Kim; Dong Jin Park; Yoontaek Lee; Ki Bum Park; Sa-Hong Min; Sang-Hoon Ahn; Hyung-Ho Kim
Journal:  Surg Endosc       Date:  2019-03-29       Impact factor: 4.584

5.  Improvement of diabetes and hypertension after gastrectomy: a nationwide cohort study.

Authors:  Eun Kyung Lee; So Young Kim; You Jin Lee; Mi Hyang Kwak; Hak Jin Kim; Il Ju Choi; Soo-Jeong Cho; Young Woo Kim; Jong Yeul Lee; Chan Gyoo Kim; Hong Man Yoon; Bang Wool Eom; Sun-Young Kong; Min Kyong Yoo; Jong Hyock Park; Keun Won Ryu
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

6.  Effect and Mechanisms of Diabetes Resolution According to the Range of Gastric Resection and the Length of Anastomosis in Animal Models: Implication for Gastric Cancer Surgery in Patients with Diabetes Mellitus.

Authors:  Yeon-Ju Huh; Young-Gil Son; Tae-Han Kim; Ji-Ho Park; Tae-Jung Oh; Boram Choi; Jimin Min; Young Min Cho; Han-Kwang Yang; Hyuk-Joon Lee
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

7.  Impact of pre-existing type-2 diabetes on patient outcomes after radical resection for gastric cancer: a retrospective cohort study.

Authors:  Zhe-Wei Wei; Jia-Ling Li; Ying Wu; Guang-Kai Xia; Roderich E Schwarz; Yu-Long He; Chang-Hua Zhang
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.199

8.  Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect.

Authors:  Wei-Jei Lee; Keong Chong; Yu-Hung Lin; Jih-Hua Wei; Shu-Chun Chen
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

9.  Overweight patients achieve ideal body weight following curative gastrectomy resulting in better long-term prognosis.

Authors:  Fanming Kong; Hui Li; Yongli Fan; Xinwei Zhang; Shui Cao; JinPu Yu; Xiubao Ren; Xishan Hao
Journal:  Obes Surg       Date:  2013-05       Impact factor: 4.129

10.  Gastric bypass procedure for type 2 diabetes patients with BMI <28 kg/m2.

Authors:  Ke Gong; Kai Li; Nengwei Zhang; Bin Zhu; Dexiao Du; Dongdong Zhang; Zhen Zhang; Jirun Peng
Journal:  Surg Endosc       Date:  2016-07-15       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.